Navigation Links
Gene signature spells poor outcome
Date:8/30/2007

Other than visually inspecting the disease, doctors have no genetic blueprint to classify melanomas, a lethal form of skin cancer. Tumors generally are ranked by how deeply the growth has invaded underlying skin tissue. The deeper it burrows into the skin, the more lethal the cancer, but some patients defy the odds and survive with thick tumors or die from thin ones. Two melanoma patients with cancers of the same invasion depth and appearance under the microscope can have completely different outcomes, says Rhoda Alani, M.D., associate professor of oncology, dermatology and molecular biology and genetics at Hopkins Kimmel Cancer Center.

Alani says the way genes turn their protein-manufacturing machinery on and off in each cancer may help create a signature that can be used to identify tumors that are more prone to kill. These so-called expression patterns can be different from one stage of cancer to the next.

Her research team charted the level of gene expression in melanoma cell lines. Three of the lines mimic the least aggressive type, which grows along the uppermost surface of the skin, called radial growth phase. Four of the cell lines are typical of so-called vertical growth phase cancers, which invade inner skin layers, and another three represent the most lethal form -metastatic melanomas.

Two vertical growth phase cell lines had gene expression patterns similar to radial growth cancers, indicating that these cells were less aggressive, according to the scientists. The remaining two vertical growth cell lines contained patterns in 18 genes that paralleled metastatic cancer cell lines, the most aggressive form. Alani and her colleagues believe that within this group of 18 genes is a signature for aggressive melanomas.

Many of the genes described in the Hopkins report, published online on July 4 in PLoS One, were previously identified as associated with aggressive cancers by scientists at Johns Hopkins and elsewhere, but Alani says her study brings them all together for melanoma and links them to an aggressive profile.

Alanis team is validating these results in human tissue samples and evaluating gene correlations with patient outcomes. Funding for the study was provided by the National Cancer Institute. With further study, the genes could be used in tests that predict a patients prognosis and as targets for tailored therapies, she says.


'/>"/>
Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Predicting Breast Cancer Recurrence By Understanding Gene Signature
2. Signature Campaign: Striking doctors take to the streets
3. Attention! Spells of momentary blindness following visual disturbance
4. Uncontrolled Diabetes Spells Doom for Dental Implants
5. Lip Service : Indiscriminate Kissing Spells Doom
6. Medicare Bulk Billing Spells Ill Health For The Health System
7. Community Health Shake-up Spells Trouble for Nurses
8. Heat Spells Trouble in South Carolina
9. The DNA That Spells Double Risk of Heart Attack
10. The DNA That Spells Double Risk of Heart Attack
11. Antifever drug betters stroke outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more ... to dairy proteins, providing direct cost savings as well as more stable pricing ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... preferred physical therapy provider for Derby City CrossFit, effective immediately. , In addition ... quickly and effectively as possible, ProRehab’s sports physical therapists will work with athletes ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... GA (PRWEB) , ... April 25, 2017 , ... ... their neck and back pain with a reputable physician in their area, announces the ... CRM protects patient information for patients who are looking for reputable physicians to help ...
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology: